February 25, 2019
Novartis taking over responsibility of cardiovascular therapy agent TQJ230 from Akcea Therapetuics
Novartis will exercise its option for worldwide responsibility of TQJ230, an investigational agent for targeted cardiovascular therapy previously known as AKCEA-APO(a)-LRx, from Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals.
